Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial.

ABSTRACT:

Background

Atypical antipsychotics are widely prescribed, yet have been associated with weight gain and metabolic syndrome.

Aim

To study the effect of adjunct low-dose aripiprazole on weight and metabolic parameters of subjects on atypical antipsychotics (olanzapine, clozapine or risperidone).

Methods

The study was carried out as an open-label trial with a fixed dose of 5 mg aripiprazole added to the patient's current antipsychotic for 12 weeks. The primary outcome measure was mean change in weight, while secondary outcome measures included change in waist circumference; fasting blood glucose; HbA1c; triglycerides; total, HDL and LDL cholesterol levels; functioning; and neurocognition.

Results

For the overall study (n = 55), there was no significant effe

SUBMITTER: Gupta B 

PROVIDER: S-EPMC8504280 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature